The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment.
about
Rifabutin for treating pulmonary tuberculosisAlternative strategies for proof-of-principle studies of antibacterial agentsLow-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosisContribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosisPopulation pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIsEarly bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis.Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trialsThe bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis.Recent developments in the treatment of tuberculosis.Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.Early bactericidal activity of antituberculosis agents.The diagnosis and therapy of tuberculosis during the past 100 years.Predicting the outcome of therapy for pulmonary tuberculosis.Tuberculosis diagnosis and multidrug resistance testing by direct sputum culture in selective broth without decontamination or centrifugation.Models and approaches for anti-TB drug testing.The early bactericidal activity of antituberculosis drugs.Time Trends in Sputum Mycobacterial Load and Two-Day Bactericidal Activity of Isoniazid-Containing Antituberculosis Therapies.A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.Assessment of the Efficacy of New Anti-Tuberculosis Drugs.Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group.Differences in EBA in the first two days of standard anti-tuberculosis treatment in different geographic regions.A reiterative method for calculating the early bactericidal activity of antituberculosis drugs.The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis.The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis.Effect of Genetic Variation of NAT2 on Isoniazid and SLCO1B1 and CES2 on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis.
P2860
Q24242892-6A12B322-7E97-4C7A-8C49-06C4F1D39C09Q26850895-536B2499-8B14-42F9-B8D0-6530357CDF80Q28379615-F6440F8B-B860-4B94-9140-8B5DB6D53E26Q28379624-2EF1B15F-911A-48F5-88E7-2E4A4F3EFA94Q31041943-045074EE-FDBB-4A5A-8BE9-C6D32FDBC01AQ33980941-5241A573-7C85-4E90-BC8C-A60541641DE6Q33982001-961EB6D6-4ECC-44A1-8BBD-E8A07A28E0B0Q34222223-3C63E862-1E75-46E1-9213-8638AF7D0122Q35185753-7EB4947C-45F2-4FA0-BAFB-673C6C2AFCB1Q35912691-1D643867-60F4-4E73-B0C3-0FF57EEEAB45Q35917156-DAEDEA60-509C-4D75-BBFA-1D8386DDEE76Q36040118-59AB3D30-3FF5-46FA-BAF2-7FECE6EFEF72Q36576104-B2518129-747D-4A64-A2F5-8D24F394E643Q36747642-A7D32109-AD6A-49FD-9ECF-43807B50FA25Q37910251-D79A87F7-8A94-4860-BF0B-8953A7C714FCQ38176039-DD53C387-191E-46A7-9E2C-AA5314A4E00EQ38991212-D7341238-AD8F-47B5-8667-E286208A1D88Q40592548-E13C9784-8CF6-4DEC-AE81-466DAC80FB35Q41572870-C4A3BE32-0B39-4ACB-BF85-89C3AE6E4330Q41876123-7987C23D-618C-4D1E-800B-2EF04B83931FQ42547475-2AE1DA73-ACF1-451F-8FA1-5F53A8E5CC44Q42580191-EDE20A2E-EF1F-48D5-9793-7573947682EFQ44045812-DE7FC054-61F2-4633-BF24-BDD7061AD8D4Q46417486-AA6328AF-F523-4EAB-B025-8A8735BB2B36Q46802151-6E9391A8-B9BD-4DA4-8DD6-3526085E4D44Q46804015-70678005-57A7-4EBC-B2FC-5E4BA3339F3BQ52742072-38B18D59-970C-4DB7-9BBD-C015A1F1B1AE
P2860
The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh-hant
name
The early bactericidal activit ...... new method of drug assessment.
@en
The early bactericidal activit ...... new method of drug assessment.
@nl
type
label
The early bactericidal activit ...... new method of drug assessment.
@en
The early bactericidal activit ...... new method of drug assessment.
@nl
prefLabel
The early bactericidal activit ...... new method of drug assessment.
@en
The early bactericidal activit ...... new method of drug assessment.
@nl
P2093
P921
P356
P1476
The early bactericidal activit ...... new method of drug assessment.
@en
P2093
Mitchison DA
Van De Wal BW
P304
P356
10.1093/JAC/32.6.867
P407
P577
1993-12-01T00:00:00Z